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Background
A vast body of evidence in animal models points to a
pivotal pathogenic role of IFNg in primary hemophago-
cytic lymphohistiocytoses (HLH). High levels of IFNg
are also found in humans with HLH.
Objectives
Given the similarities between primary and secondary
HLH (sec-HLH), including MAS, we measured levels of
IFNg, IFNg-related chemokines (CXCL9, CXCL10,
CXLC11), and IL-6 in patients with sec-HLH, and in
patients with systemic Juvenile Idiopathic Arthritis
(sJIA) with or without MAS at sampling and evaluated
their relation to disease activity. In addition, we evalu-
ated the correlation between serum levels of IFNg and
of the three IFNg related chemokines with themselves
and with laboratory parameters of disease activity in
patients with active MAS.
Methods
We measured circulating levels of IFNg, CXCL9,
CXCL10, CXCL11 and IL-6 in patients with sJIA (n=54)
of whom 20 had MAS at time of sampling using the
Luminex multiplexing assay.
Results
Levels of IFNg and of IFNg-related chemokines (median
pg/ml(IQR)) were markedly elevated in active MAS and
active sec-HLH, with no significant differences between
active sec-HLH (IFNg 34.7 (23.9-170.1); CXCL9 33598
(3083-127687); CXCL10 4420 (799.7-8226); CXCL11
1327 (189-2000)) and active MAS (IFNg 15.4 (5.1-52.6);
CXCL9 13392 (2163-35452); CXCL10 1612 (424.8-
4309); CXCL11 564.8 (197.5-1007)). Levels in active
sJIA without MAS at sampling were lower (all p values
2=0.47; p=0.001), to a lesser extent of CXCL10 (r=0.53;
r2=0.28; p=0.015), and not of CXCL11 (r=-0.04;p=0.886).
In active MAS ferritin, neutrophils, platelets, alanine
aminotransferase and lactate dehydrogenase were signifi-
cantly correlated with IFNg and CXCL9, and to a lesser
extent with CXCL10 and CXCL11; no correlation with
IL-6 levels was found. In patients with active sJIA with-
out MAS there was no significant correlation between
laboratory parameters and cytokine levels (Table 1).
Conclusions
IFNg, and IFNg-related chemokines, levels were
increased in patients with MAS compared to patients
with active sJIA without MAS. The high levels of IFNg
and of CXCL9 present in patients with active MAS were
significantly correlated with laboratory parameters of
disease severity. In patients with active MAS IFNg and
CXCL9 are tightly correlated. Since CXCL9 has been
shown to be induced only by IFNg and not by other
interferons [1], our findings support the conclusion that
CXCL9 is a potential biomarker of IFNg production in
MAS.
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Table 1. Correlation of laboratory parameters of disease activity with IFN-g, CXCL9, CXCL10, CXCL11 and IL-6 in
patients with MAS and in patients with active sJIA
Macrophage Activation Syndrome IFNg CXCL9 CXCL10 CXCL11 IL-6
r* p r* p r* p r* p r* p
Ferritin 8000 (3158 - 13174) [1] 0.57 0.014 0.49 0.041 0.66 0.002 0.62 0.023 0.17 >0.1
N 6.9 (3.4 - 13.9) [1] -0.64 0.005 -0.61 0.010 -0.37 >0.1 -0.08 >0.1 0.09 >0.1
PLT 197 (114 - 392) [1] -0.53 0.017 -0.52 0.022 -0.58 0.008 -0.22 >0.1 -0.02 >0.1
ALT 46 (18 - 164) [1] 0.49 0.045 0.49 0.044 0.51 0.038 0.06 >0.1 -0.44 0.080
LDH 1152 (722 - 2135) [1] 0.45 0.095 0.62 0.013 0.64 0.001 0.64 0.048 0.08 >0.1
Sistemic Juvenile Idiopathic Arthritis r* p r* p r* p r* P r* p
Ferritin 214 (37 - 1669) [1] -0.27 >0.1 0.28 >0.1 0.27 >0.1 0.29 >0.1 -0.12 >0.1
N 8.4 (5.2 - 14.5) [1] 0.30 >0.1 0.40 0.061 0.32 >0.1 0.40 0.067 0.28 >0.1
PLT 444 (353 - 544) [1] 0.21 >0.1 -0.14 >0.1 -0.13 >0.1 0.27 >0.1 0.35 0.064
ALT 16 (11 - 24) [1] 0.29 >0.1 0.42 0.049 0.50 0.011 0.44 0.039 0.04 >0.1
LDH 506 (455 - 851) [1] 0.07 >0.1 0.49 >0.1 0 >0.1 0.26 >0.1 0 >0.1
N=neutrophil count; PLT=platelet count; ALT=alanine aminotransferase; LDH=lactate dehydrogenase; [1]= Median (IQR); r*= Spearman r.
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